Lexeo Therapeutics, Inc. Logo

Lexeo Therapeutics, Inc.

Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.

LXEO | US

Overview

Corporate Details

ISIN(s):
US52886X1072
LEI:
Country:
United States of America
Address:
345 PARK AVENUE SOUTH, 10010 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing curative treatments for genetically defined diseases. The company advances a pipeline of investigational AAV-mediated gene therapies, with a primary focus on genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. Building on foundational research from Weill Cornell Medicine and the University of California San Diego, Lexeo's strategy prioritizes efficient development, advanced manufacturing, and strategic partnerships with leading research institutions to develop high-impact therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lexeo Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lexeo Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lexeo Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany
VVY
VivoSim Labs, INC. Logo
Offers 3D human tissue models for predictive toxicology testing to accelerate drug discovery.
United States of America
VIVS
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea
082800
VOLITIONRX LTD Logo
Develops epigenetic blood tests for early cancer and sepsis detection in human/veterinary markets.
United States of America
VNRX
vTv Therapeutics Inc. Logo
Develops oral small molecule drugs for type 1 diabetes and other chronic conditions.
United States of America
VTVT
VYNE Therapeutics Inc. Logo
Clinical-stage biopharma developing novel therapies for immuno-inflammatory diseases.
United States of America
VYNE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan
4512
Wave Life Sciences Ltd. Logo
Developing RNA-based medicines for severe genetic diseases like DMD and Huntington's disease.
United States of America
WVE
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea
010600
Werewolf Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
United States of America
HOWL

Talk to a Data Expert

Have a question? We'll get back to you promptly.